[{"orgOrder":0,"company":"Fujifilm Toyama Chemical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fujifilm Toyama Chemical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Fujifilm Toyama Chemical \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Fujifilm Toyama Chemical \/ Not Applicable"},{"orgOrder":0,"company":"Novus Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"DPPC","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Novus Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"","sponsorNew":"Novus Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novus Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Novus Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"DPPC","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Novus Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Novus Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novus Therapeutics, Inc \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for DPPC

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Although the study did not achieve statistical significance for the primary efficacy endpoints, But the statistical trend were encouraging that favored the OP0201 treatment group with regard to resolution of middle ear effusion.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 01, 2020

                          Lead Product(s) : DPPC,Cholesteryl Palmitate

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Patients who were given the medicine in Shenzhen turned negative for the virus after a median of four days after becoming positive compared to theose who were not treated with the drug.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 18, 2020

                          Lead Product(s) : Favipiravir,DPPC,Cholesteryl Palmitate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Study is assessing the safety, tolerability, and efficacy of 20 mg/day intranasal OP0201 as an adjunct therapy to oral antibiotic treatment of acute otitis media in infants and 6 to 24 months olds.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 02, 2020

                          Lead Product(s) : DPPC,Cholesteryl Palmitate

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank